-David Montefiori Researcher Activity Profile

Research Author Detailed Information 

David Montefiori Publication Rate By Year

David Montefiori has published 6 paper(s) in 2007, 5 paper(s) in 2008, for a total of 11 research publications in total.

David D Montefiori Author Information

LAST NAME: montefiori

FIRST NAME: david

INITIALS: D

AFFILIATION:

Papers

David Montefiori's Publication Record

1. Antiviral antibodies are necessary for control of simian immunodeficiency virus replication. Year Published: 2007
Center for Comparative Medicine, California National Primate Research Center, University of California, Davis, Davis, California 95616, USA. cjmiller@ucdavis.edu
2. Immunogenicity of recombinant human immunodeficiency virus type 1-like particles expressing gp41 derivatives in a pre-fusion state. Year Published: 2007
Laboratory of Immunobiology, Department of Medical Oncology, Dana-Farber Cancer Institute and Department of Medicine, Harvard Medical School, Boston, MA 02115, United States.
3. Antibody-based HIV-1 vaccines: recent developments and future directions. Year Published: 2007
Duke University Medical Center, Durham, North Carolina, United States of America. monte@duke.edu
4. Betulinic Acid Derivatives That Target gp120 and Inhibit Multiple Genetic Subtypes of Human Immunodeficiency Virus Type 1. Year Published: 2007
Duke University Medical Center, Box 2826, Durham, NC 27710-2926. chc@duke.edu.
5. Antibody-Based HIV-1 Vaccines: Recent Developments and Future Directions. Year Published: 2007
6. Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses. Year Published: 2008
Washington National Primate Center, University of Washington, 3000 Western Ave., Seattle, WA 98121, USA.
7. Antibody-based HIV-1 vaccines: recent developments and future directions. Year Published: 2007
Duke University Medical Center, Durham, North Carolina, United States of America. monte@duke.edu
8. Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope. Year Published: 2008
Novartis Vaccines and Diagnostics, Inc., 4560 Horton Street, Emeryville, California 94608, USA.
9. Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses. Year Published: 2008
Washington National Primate Center, University of Washington, 3000 Western Ave., Seattle, WA 98121, USA.
10. Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope. Year Published: 2008
Novartis Vaccines and Diagnostics, Inc., 4560 Horton Street, Emeryville, California 94608, USA.
11. DNA-MVA Vaccine Protection after X4 SHIV Challenge in Macaques Correlates with Day-of-Challenge Antiviral CD4(+) Cell-Mediated Immunity Levels and Postchallenge Preservation of CD4(+) T Cell Memory. Year Published: 2008
Department of Medicine, Children's Hospital Boston, Dana Farber Cancer Institute, Boston, Massachusetts 02115., Department of Pediatrics, Harvard Medical School, Dana Farber Cancer Institute, Boston, Massachusetts 02115.